![logo](/logos/VSTM.webp)
Verastem, Inc.
NASDAQ:VSTM
2.4 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Verastem, Inc. |
Symbool | VSTM |
Munteenheid | USD |
Prijs | 2.4 |
Beurswaarde | 96,584,880 |
Dividendpercentage | 0% |
52-weken bereik | 2.1 - 14.22 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Daniel W. Paterson |
Website | https://www.verastem.com |
An error occurred while fetching data.
Over Verastem, Inc.
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)